PIK3CA and breast carcinoma: A subset of the alterations that we identified can also guide combinatorial therapeutic strategies since these alterations conferred resistance and are targets of current FDA approved drugs, creating an opportunity for the precision targeting of therapeutic resistance (for example, AR expression and anti-androgens in breast cancer and NFE2L2 activation and anti-PI3K therapies in NSCLC8, 57, 58).